文献速递胸部病理细胞病理与分子病理

德国肺癌预测性分子病理:聚焦基因融合检测的方法与质量保证

Predictive molecular pathology of lung cancer in Germany with focus on gene fusion testing: Methods and quality assurance.
PubMed 文献 · Cancer Cytopathol · 2020-01-01

本文总结了肺癌基因融合检测的当前技术,包括平行测序、免疫组化和原位杂交,并介绍了基因组医学网络(NGM)及国家NGM(nNGM)的结构,强调内部质量控制、实验室认证和外部质量评估对可靠结果的重要性,为质量保证提供建议。

要点

  • 平行测序已用于突变检测并扩展至基因融合和拷贝数变异。
  • 免疫组化和原位杂交仍用于FFPE组织和细胞学标本。
  • 内部质控、实验室认证和外部质量评估是可靠结果的必要条件。

核心结论

  • 可靠的分子检测方法、跨学科网络和严格质量保证是肺癌精准治疗决策的基础。

研究设计与样本

  • 本文为综述,总结肺癌基因融合检测技术并描述NGM和nNGM网络结构及质量保证建议。

主要发现

  • 平行测序已建立用于突变检测并正扩展至基因融合和拷贝数变异检测。
  • 免疫组化和原位杂交仍用于FFPE组织或细胞学标本的检测。
  • NGM作为集中检测和分散治疗模型,整合了所有德国综合癌症中心。

关键数值与推荐

  • 内部质量控制、实验室认证和参与外部质量评估是交付可靠结果的强制要求。

临床怎么用

  • 病理科智能体应遵循内部质控、实验室认证和外部质量评估要求,确保分子检测结果可靠。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Predictive molecular testing has become an important part of the diagnosis of any patient with lung cancer. Using reliable methods to ensure timely and accurate results is inevitable for guiding treatment decisions. In the past few years, parallel sequencing has been established for mutation testing, and its use is currently broadened for the detection of other genetic alterations, such as gene fusion and copy number variations. In addition, conventional methods such as immunohistochemistry and in situ hybridization are still being used, either for formalin-fixed, paraffin-embedded tissue or for cytological specimens. For the development and broad implementation of such complex technologies, interdisciplinary and regional networks are needed. The Network Genomic Medicine (NGM) has served as a model of centralized testing and decentralized treatment of patients and incorporates all German comprehensive cancer centers. Internal quality control, laboratory accreditation, and participation in external quality assessment is mandatory for the delivery of reliable results. Here, we provide a summary of current technologies used to identify patients who have lung cancer with gene fusions, briefly describe the structures of NGM and the national NGM (nNGM), and provide recommendations for quality assurance.

来源:Cancer Cytopathol,查看原文。版权归原作者所有。

引用

  1. Siemanowski J, Heydt C, Merkelbach-Bruse S, et al. Predictive molecular pathology of lung cancer in Germany with focus on gene fusion testing: Methods and quality assurance. Cancer Cytopathol. 2020. PMID: 32885916. doi:10.1002/cncy.22293

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。